23 results
10-Q
2021 Q2
CADL
Candel Therapeutics Inc
8 Sep 21
Quarterly report
8:37am
, and our research and development programs;
the ultimate impact of the current novel coronavirus, or COVID-19, pandemic, or any other health epidemic … as a whole;
risks related to the direct or indirect impact of the COVID-19 pandemic or any future large-scale adverse health event, such as the scope
10-K
09t nl14vp
29 Mar 22
Annual report
8:46am
S-1
k5no1qo94sqz
25 Jun 21
IPO registration
5:28pm
DRS/A
eoybf93ndxf
31 Mar 21
Draft registration statement (amended)
12:00am
S-1/A
3efp8ed
16 Jul 21
IPO registration (amended)
6:07am
424B4
tgo05ecd37gpqoh5
28 Jul 21
Prospectus supplement with pricing info
4:02pm
CORRESP
uc5y 5n94bzlp
7 Jul 21
Correspondence with SEC
12:00am
8-K
EX-99.1
q0dsf
6 Jun 22
Regulation FD Disclosure
8:37am
DEF 14A
4du1nzr2 ci
2 Sep 22
Definitive proxy
8:30am
8-K
EX-99.1
0v7tf516
6 Dec 22
Regulation FD Disclosure
8:01am
S-3
y4vxauerdu 7nmodb
5 Aug 22
Shelf registration
5:08pm